secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001193125-26-139094
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics founder Howard Berman steps down as Executive Chairman; Mark Pavao appointed independent director
--------------------------------------------------------------------------------

- Howard Berman resigned as Executive Chairman and Board member effective April 1, 2026; part of planned CEO transition initiated November 2024.
- Separation agreement includes prorated 2026 bonus at 100% target, COBRA coverage through March 2027, and continued vesting of stock options for 12 months.
- Mark H. Pavao appointed as independent Class III director, term expiring at 2028 annual meeting; granted option for 10,000 shares vesting in one year.
- Pavao brings 30+ years of biopharma commercial experience, including roles at Bristol-Myers Squibb and R-Pharm US.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526139094/0001193125-26-139094-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526139094/d104763d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-139094

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer